40853-88-1

Usage

Uses

Used in Pharmaceutical and Therapeutic Applications:
(Z)-9-Hexadecen-1-amine is used as an active compound for its antimicrobial and anti-inflammatory properties. It aids in the development of new drugs and therapies targeting various diseases and conditions.
Used in Biochemical Research:
(Z)-9-Hexadecen-1-amine is used as a research compound for studying its role in cell signaling, neurotransmission, and lipid metabolism. This helps in understanding the underlying mechanisms of various biological processes and the potential for developing new treatments.
Used in Medicine:
(Z)-9-Hexadecen-1-amine is used as a therapeutic agent for its potential applications in treating conditions related to inflammation and microbial infections. Its properties make it a promising candidate for the development of new medical treatments.
Used in the Cosmetics Industry:
(Z)-9-Hexadecen-1-amine can be used as an ingredient in cosmetics for its potential anti-inflammatory and antimicrobial properties, which may contribute to the development of products with skin-soothing and protective effects.

InChI:InChI=1/C16H33N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h7-8H,2-6,9-17H2,1H3/b8-7+

Upstream product

• 373-49-9 cis-9-hexadecenoic acid 
• 93135-85-4 palmitoleyl methanesulfonate 

Relevant academic research and scientific papers

A biocatalytic cascade for the conversion of fatty acids to fatty amines

Fatty amine synthesis from renewable sources is an energetically-demanding process involving toxic metal catalysts and harsh reaction conditions as well as selectivity problems. Herein we present a mild, biocatalytic alternative to the conventional amination of fatty acids through a one-pot tandem cascade performed by a carboxylic acid reductase (CAR) and a transaminase (ω-TA). Saturated and unsaturated fatty acids, with carbon chain lengths ranging from C6 to C18, were successfully aminated obtaining conversions of up to 96%.

Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles

We report a potent cationic lipid, SST-02 ((3-hydroxylpropyl)dilinoleylamine), which possesses a simple chemical structure and is synthesized just in one step. Cationic lipids are key components of siRNA-lipid nanoparticles (LNP), which may serve as potential therapeutic agents for various diseases. For a decade, chemists have given enhanced potency and new functions to cationic lipids along with structural complexity. In this study, we conducted a medicinal chemistry campaign pursuing chemical simplicity and found that even dilinoleylmethylamine (SST-01) and methylpalmitoleylamine could be used for the in vitro and in vivo siRNA delivery. Further optimization revealed that a hydroxyl group boosted potency, and SST-02 showed an ID50 of 0.02 mg/kg in the factor VII (FVII) model. Rats administered with 3 mg/kg of SST-02 LNP did not show changes in body weight, blood chemistry, or hematological parameters, while the AST level decreased at a dose of 5 mg/kg. The use of SST-02 avoids a lengthy synthetic route and may thus decrease the future cost of nucleic acid therapeutics.